Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share
